Previous 10 | Next 10 |
Athersys, Inc. (ATHX) Q2 2019 Earnings Conference Call August 07, 2019, 16:30 ET Company Participants Karen Hunady - Director, Corporate Communications & IR Laura Campbell - SVP, Finance William Lehmann - President, COO & Secretary Conference Call Participants Jason...
Athersys (NASDAQ: ATHX ): Q2 GAAP EPS of -$0.06 beats by $0.03 . Revenue of $4.3M (-77.8% Y/Y) beats by $2.82M . Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, ,
CLEVELAND, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019. Highlights of the second quarter of 2019 and recent events include: Received Fast Track designation from the FDA for our clin...
CLEVELAND, July 08, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the resu...
XpresSpa Group (NASDAQ: XSPA ) -53% . More news on: XpresSpa Group, Inc., Aclaris Therapeutics, Inc., Pier 1 Imports, Inc., Stocks on the move, Read more ...
Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...
Introduction The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 ye...
CLEVELAND, June 04, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will ta...
CLEVELAND, May 28, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy (ISCT) conference taking place May 29 – June 2, 2019 in Melbourne, Australia. ISCT 201...
CLEVELAND, May 20, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...